{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:09:12Z","timestamp":1790024952928,"version":"4.0.1"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009104","name":"University of Modena and Reggio Emilia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.critrevonc.2024.104607","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T07:14:11Z","timestamp":1735110851000},"page":"104607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Suppressing, stimulating and\/or inhibiting: The evolving management of HCC patient after liver transplantation"],"prefix":"10.1016","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-7010","authenticated-orcid":false,"given":"Lorenza","family":"Di Marco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Romanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pivetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ravaioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Salati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Magistri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Di Sandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Spallanzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104607_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2024.104607_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104607_bib3","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2024.104607_bib4","article-title":"Anti-Programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases","volume":"12","author":"Al Jarroudi","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2024.104607_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jceh.2019.11.009","article-title":"Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab","volume":"10","author":"Amjad","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib6","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000416","article-title":"Nivolumab-induced autoimmune-like cholestatic hepatitis in a liver transplant recipient","volume":"7","author":"Anugwom","year":"2020","journal-title":"ACG Case Rep. J."},{"key":"10.1016\/j.critrevonc.2024.104607_bib7","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.3748\/wjg.v24.i45.5081","article-title":"Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: a proposed management algorithm","volume":"24","author":"Au","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib8","first-page":"172","article-title":"Steroid-resistant acute rejections after liver transplant","volume":"8","author":"Aydogan","year":"2010","journal-title":"Exp. Clin. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib9","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/cam4.5123","article-title":"Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation","volume":"12","author":"Bang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2024.104607_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.athoracsur.2007.10.065","article-title":"Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation","volume":"85","author":"Bates","year":"2008","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.critrevonc.2024.104607_bib11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/TP.0000000000003196","article-title":"Posttransplant Management Of Recipients Undergoing Liver Transplantation For Hepatocellular Carcinoma. Working Group Report from the ILTS transplant oncology consensus conference","volume":"104","author":"Berenguer","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0000000000001894","article-title":"Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics","volume":"266","author":"Bodzin","year":"2017","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2024.104607_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104607_bib14","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2024.104607_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jamcollsurg.2003.07.003","article-title":"Predictors and patterns of recurrence after resection of hepatocellular carcinoma","volume":"197","author":"Cha","year":"2003","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.critrevonc.2024.104607_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/lt.24117","article-title":"Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation","volume":"21","author":"Chaiteerakij","year":"2015","journal-title":"Liver Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/TP.0000000000002647","article-title":"Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients","volume":"103","author":"Chen","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib20","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1007\/s00268-011-1146-z","article-title":"Late recurrence of hepatocellular carcinoma after liver transplantation","volume":"35","author":"Chok","year":"2011","journal-title":"World J. Surg."},{"key":"10.1016\/j.critrevonc.2024.104607_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jceh.2017.10.003","article-title":"Acute and chronic rejection after liver transplantation: what a clinician needs to know","volume":"7","author":"Choudhary","year":"2017","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1600-6143.2006.01719.x","article-title":"Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria","volume":"7","author":"Cillo","year":"2007","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib23","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/TP.0000000000003998","article-title":"De novo malignancy after liver transplantation: risk assessment, prevention, and management-guidelines from the ILTS-SETH consensus conference","volume":"106","author":"Colmenero","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12906","article-title":"Why do patients die after a liver transplantation?","volume":"31","author":"Daniel","year":"2017","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib25","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/TP.0000000000004108","article-title":"The impact of treatment of hepatocellular carcinoma with immune checkpoint inhibitors on pre- and post-liver transplant outcomes","volume":"106","author":"Dave","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib27","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","article-title":"Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient","volume":"152","author":"De Toni","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2024.104607_bib28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1526924816664083","article-title":"Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation","volume":"26","author":"de\u2019Angelis","year":"2016","journal-title":"Prog. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11523-011-0177-6","article-title":"Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors","volume":"6","author":"Delbaldo","year":"2011","journal-title":"Targ. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib30","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/TP.0000000000003292","article-title":"Immune checkpoint inhibitors in transplantation-a case series and comprehensive review of current knowledge","volume":"105","author":"Delyon","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib32","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.3748\/wjg.v28.i36.5250","article-title":"Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma","volume":"28","author":"Devan","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/LVT.0000000000000087","article-title":"Feasibility, safety, and outcome of second-line nivolumab\/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma","volume":"29","author":"Di Marco","year":"2023","journal-title":"Liver Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib34","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/onc.2013.92","article-title":"Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors","volume":"33","author":"Ducker","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2024.104607_bib35","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2024.104607_bib36","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104607_bib37","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2024.104607_bib38","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.transproceed.2007.06.042","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation","volume":"39","author":"Escartin","year":"2007","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.critrevonc.2024.104607_bib39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2147\/JHC.S381764","article-title":"Tumor microenvironment in hepatocellular carcinoma: key players for immunotherapy","volume":"9","author":"Feng","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.critrevonc.2024.104607_bib41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/lt.24742","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?","volume":"23","author":"Fernandez-Sevilla","year":"2017","journal-title":"Liver Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib42","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune checkpoint inhibitors in solid organ transplant recipients with advanced skin cancers-emerging strategies for clinical management","volume":"107","author":"Ferr\u00e1ndiz-Pulido","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13997","article-title":"A short overview on mycophenolic acid pharmacology and pharmacokinetics","volume":"34","author":"Ferreira","year":"2020","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib44","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib45","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104607_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2024.104607_bib47","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1084\/jem.20182395","article-title":"Development of immune checkpoint therapy for cancer","volume":"216","author":"Fritz","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2024.104607_bib48","article-title":"Liver allograft failure after nivolumab treatment-a case report with systematic literature research","volume":"4","author":"Gassmann","year":"2018","journal-title":"Transpl. Direct"},{"key":"10.1016\/j.critrevonc.2024.104607_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655697","article-title":"Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies","volume":"12","author":"Giraud","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Gomez-Martin","year":"2012","journal-title":"Liver Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2024.104607_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/SLA.0b013e3181a77e59","article-title":"Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma","volume":"250","author":"Halazun","year":"2009","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2024.104607_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.lungcan.2010.02.014","article-title":"Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma","volume":"70","author":"Han","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104607_bib55","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdi182","article-title":"Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor","volume":"16","author":"Hara","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.21037\/hbsn-22-579","article-title":"Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives","volume":"13","author":"Herrero","year":"2024","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.critrevonc.2024.104607_bib57","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.surg.2011.12.015","article-title":"Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities","volume":"151","author":"Ho","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.critrevonc.2024.104607_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/17474124.2021.1823213","article-title":"Recurrence of hepatocellular carcinoma following liver transplantation","volume":"15","author":"Hoffman","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2024.104607_bib60","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/toxsci\/kfz112","article-title":"Hepatocyte-derived exosomes promote liver immune tolerance: possible implications for idiosyncratic drug-induced liver injury","volume":"170","author":"Holman","year":"2019","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104607_bib61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41586-022-04916-6","article-title":"Immune tolerance of food is mediated by layers of CD4+ T cell dysfunction","volume":"607","author":"Hong","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2024.104607_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000310","article-title":"Post-transplant malignancy in liver transplantation: a single center experience","volume":"93","author":"Hsiao","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.critrevonc.2024.104607_bib63","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jss.2015.07.033","article-title":"Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation?","volume":"200","author":"Huang","year":"2016","journal-title":"J. Surg. Res"},{"key":"10.1016\/j.critrevonc.2024.104607_bib64","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Iavarone","year":"2019","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib65","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/lt.26264","article-title":"Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study","volume":"27","author":"Iavarone","year":"2021","journal-title":"Liver Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib66","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0000000000002955","article-title":"Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation","volume":"104","author":"Invernizzi","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2024.104607_bib68","article-title":"Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4143\/crt.2016.066","article-title":"Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma","volume":"49","author":"Jung","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2024.104607_bib70","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","article-title":"Tremelimumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2024.104607_bib72","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib73","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3348\/kjr.2007.8.4.320","article-title":"Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation","volume":"8","author":"Ko","year":"2007","journal-title":"Korean J. Radiol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejso.2009.10.001","article-title":"Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables","volume":"36","author":"Kornberg","year":"2010","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib75","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104607_bib76","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib77","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/vaccines9050532","article-title":"The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment","volume":"9","author":"Leone","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104607_bib78","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib79","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib80","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104607_bib81","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.transproceed.2019.12.016","article-title":"Efficacy and safety of sorafenib after liver transplantation: experience in our center","volume":"52","author":"L\u00f3pez Ortega","year":"2020","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.critrevonc.2024.104607_bib82","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027082","article-title":"Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report with long term follow-up outcomes","volume":"100","author":"Mahn","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.critrevonc.2024.104607_bib83","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","article-title":"The yin and yang of evasion and immune activation in HCC","volume":"62","author":"Makarova-Rusher","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib84","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib85","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.3748\/wjg.v26.i24.3326","article-title":"Non-invasive tests for the prediction of primary hepatocellular carcinoma","volume":"26","author":"Marasco","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib86","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","article-title":"Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends","volume":"60","author":"Matter","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib87","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib88","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104607_bib89","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2217\/fon.15.239","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: an update","volume":"11","author":"Mazzola","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib90","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.critrevonc.2024.104607_bib91","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/ajt.14549","article-title":"Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database","volume":"18","author":"Mehta","year":"2018","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib92","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081909","article-title":"The role of immunotherapy in a tolerogenic environment: current and future perspectives for hepatocellular carcinoma","volume":"10","author":"Montella","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2024.104607_bib94","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","article-title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","volume":"3","author":"Morales","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104607_bib95","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104607_bib96","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/2050640618774631","article-title":"Use of checkpoint inhibitors in liver transplant recipients","volume":"6","author":"Munker","year":"2018","journal-title":"U. Eur. Gastroenterol. J."},{"key":"10.1016\/j.critrevonc.2024.104607_bib97","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1432-2277.2010.01143.x","article-title":"Current views on rejection pathology in liver transplantation","volume":"23","author":"Neil","year":"2010","journal-title":"Transpl. Int."},{"key":"10.1016\/j.critrevonc.2024.104607_bib98","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/bs.acr.2019.03.003","article-title":"Co-stimulatory and co-inhibitory pathways in cancer immunotherapy","volume":"143","author":"O\u2019Neill","year":"2019","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104607_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.898964","article-title":"Immune checkpoint inhibitors for advanced hepatocellular carcinoma: monotherapies and combined therapies","volume":"12","author":"Ouyang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2217\/imt-2020-0014","article-title":"Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection","volume":"12","author":"Pandey","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2024.104607_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2024.104607_bib102","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194882","article-title":"Management of hepatocellular carcinoma recurrence after liver transplantation","volume":"13","author":"Pelizzaro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104607_bib104","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-based therapies for hepatocellular carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2024.104607_bib105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5500\/wjt.v10.i11.297","article-title":"Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?","volume":"10","author":"Pi\u00f1ero","year":"2020","journal-title":"World J. Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib106","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib107","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?","volume":"67","author":"Rammohan","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2024.104607_bib108","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib109","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib111","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib112","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ctr.12286","article-title":"The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation","volume":"28","author":"Roh","year":"2014","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.critrevonc.2024.104607_bib113","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1432-2277.2005.00200.x","article-title":"A case of acute humoral rejection in liver transplantation: successful treatment with plasmapheresis and mycophenolate mofetil","volume":"18","author":"Rostron","year":"2005","journal-title":"Transpl. Int."},{"key":"10.1016\/j.critrevonc.2024.104607_bib114","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.21037\/jgo-22-922","article-title":"Immune checkpoint inhibitors in liver transplant: a case series","volume":"14","author":"Rudolph","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib116","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1007\/s10620-010-1149-x","article-title":"Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation","volume":"55","author":"Schmitt","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.critrevonc.2024.104607_bib117","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/L17-0187","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma","volume":"167","author":"Schvartsman","year":"2017","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.critrevonc.2024.104607_bib118","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s10620-011-1910-9","article-title":"Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era","volume":"57","author":"Sharma","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.critrevonc.2024.104607_bib119","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1273309","article-title":"PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma","volume":"6","author":"Sideras","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2024.104607_bib120","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3748\/wjg.v28.i34.4929","article-title":"Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma","volume":"28","author":"Sposito","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib121","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4252\/wjsc.v13.i7.795","article-title":"Immunotherapy against programmed death-1\/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells","volume":"13","author":"Sukowati","year":"2021","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.critrevonc.2024.104607_bib122","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2024.104607_bib123","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104607_bib124","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.27787","article-title":"Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation","volume":"62","author":"Toso","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2024.104607_bib125","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.2174\/1381612826666200429093648","article-title":"Hepatocellular carcinoma in non alcoholic fatty liver disease","volume":"26","author":"Tovoli","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.critrevonc.2024.104607_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081558","article-title":"Effect of mycophenolate mofetil therapy on recurrence of hepatocellular carcinoma after liver transplantation: a population-based cohort study","volume":"10","author":"Tsai","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2024.104607_bib127","doi-asserted-by":"crossref","first-page":"273","DOI":"10.21037\/atm.2016.07.14","article-title":"Future perspectives in cancer immunotherapy","volume":"4","author":"Tsiatas","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104607_bib128","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.transproceed.2010.02.014","article-title":"Management of hepatocellular carcinoma recurrence after liver transplantation","volume":"42","author":"Valdivieso","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.critrevonc.2024.104607_bib129","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/ajg.2017.387","article-title":"Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma","volume":"112","author":"Varkaris","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: Management after the transplant","volume":"20","author":"Verna","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.critrevonc.2024.104607_bib131","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104607_bib132","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/LVT.0000000000000083","article-title":"Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss","volume":"29","author":"Wang","year":"2023","journal-title":"Liver Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib133","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/lt.26416","article-title":"Preliminary evaluation of atezolizumab plus bevacizumab as salvage treatment for recurrent hepatocellular carcinoma after liver transplantation","volume":"28","author":"Yang","year":"2022","journal-title":"Liver Transpl."},{"key":"10.1016\/j.critrevonc.2024.104607_bib134","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.hbpd.2020.06.002","article-title":"Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: preliminary experience","volume":"19","author":"Yang","year":"2020","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.critrevonc.2024.104607_bib135","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib136","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib137","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3109\/02656736.2015.1091953","article-title":"Microwave ablation in treating intrahepatic recurrence of hepatocellular carcinoma after liver transplantation: an analysis of 11 cases","volume":"31","author":"Zhai","year":"2015","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.critrevonc.2024.104607_bib138","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jvir.2009.11.006","article-title":"Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation","volume":"21","author":"Zhou","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib139","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2024.104607_bib140","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib141","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104607_bib142","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.hbpd.2019.09.011","article-title":"Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation","volume":"19","author":"Zhuang","year":"2020","journal-title":"Hepatobiliary Pancreat. Dis. Int."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:17Z","timestamp":1740144197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824003500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":142,"alternative-id":["S1040842824003500"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104607","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppressing, stimulating and\/or inhibiting: The evolving management of HCC patient after liver transplantation","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104607"}}